Core Viewpoint - Xianle Health, a leading health supplement OEM, has submitted an application for a dual listing on the Hong Kong Stock Exchange, while simultaneously announcing a significant decline in net profit for the previous year [1][2] Group 1: Company Performance - Xianle Health's revenue for 2023, 2024, and the first three quarters of 2025 is projected to be 3.582 billion, 4.211 billion, and 3.291 billion yuan respectively, with net profit growth rates declining significantly to 32.39%, 15.66%, and 8.53% [1] - The company expects a net profit attributable to shareholders for 2025 to be between 101 million and 151 million yuan, representing a year-on-year decline of 53% to 69% [2] - The net profit margin for the same periods is reported at 6.71%, 6.7%, and 6.74%, indicating a stable but low profitability [1] Group 2: Business Strategy and Adjustments - The decline in net profit is attributed to a one-time asset impairment loss of 195 million yuan from the personal care business, which has been underperforming and is being divested [2] - The company is focusing on strategic consulting projects and investments in emerging sectors such as precision nutrition and pet nutrition, which have incurred initial costs affecting profit margins [2] - A new stock incentive plan has been proposed, aiming to grant 2.2025 million restricted shares to 85 key personnel, with revenue targets set for 2026 to 2028 but no profit-related metrics, raising concerns among investors [3] Group 3: Market Outlook and Analyst Opinions - Analysts express optimism regarding Xianle Health's growth in European and Asia-Pacific markets, suggesting that the company can leverage international capital markets to enhance its global strategy [4] - The divestment of the personal care business allows the company to concentrate on its core operations, potentially leading to improved profitability and growth in both domestic and international markets [4] - Analysts recommend monitoring the company's performance as it aims for accelerated growth in emerging channels and overseas markets [4]

中国营养健康食品行业的龙头企业仙乐健康，在1月30日向市场投下了一枚重磅消息：公司已正式向香港联交所递交主板上市申请，同步披露申请材料，迈 出了构建"A+H"双资本平台的关键一步。 值得注意的是，这一战略性举措，恰逢公司披露2025年业绩预告，其归母净利润预计出现较大幅度下滑，引发了市场对其发展前景的广泛关注。 当前，全球营养健康食品市场正处快速扩张期，尤其是软胶囊、软糖等细分赛道增速显著。通过建立"A+H"双平台，仙乐健康不仅能优化资本结构，更能提 升国际品牌声誉，为其在海外市场拓展、供应链全球优化及潜在并购提供强有力的资金与平台支持，从而在行业黄金增长期中抢占更有利的竞争位置。 长远来看，这一战略转型有望为公司打开新的成长空间。剥离非核心业务有助于"轻装上阵"，集中资源巩固在营养健康解决方案领域的领先优势。 一方面，公司对协同效应有限的个人护理业务计提了高达1.95亿元的资产减值损失，为其剥离做财务准备，这一举措虽影响当期利润，但长远看将使公司更 加聚焦于营养健康食品解决方案的核心主业。 另一方面，公司在精准营养、宠物营养等新兴领域的前期战略性投入，以及为全球化战略启动的咨询项目费用，也在短期内增加了支出 ...

Core Viewpoint - Xianle Health is expected to report a significant decline in net profit for 2025, with estimates ranging from 101 million to 151 million yuan, representing a year-on-year drop of 53% to 69%. The non-recurring net profit is projected to decrease by 74% to 82%, amounting to between 57.5 million and 85.97 million yuan. This performance shift is attributed to multiple factors, including non-core business losses, strategic investments, and changes in the industry environment [1][6]. Financial Performance Overview - From 2022 to 2024, Xianle Health's revenue grew from 2.507 billion yuan to 4.211 billion yuan, with year-on-year growth rates of 5.84%, 42.87%, and 17.56% respectively. Net profit increased from 212 million yuan to 325 million yuan, with year-on-year growth rates of -8.43%, 32.39%, and 15.66% [1][6]. - In the first three quarters of 2025, the company reported revenue of 3.291 billion yuan, a year-on-year increase of 7.96%, and a net profit of 260 million yuan, up 8.53%, indicating that the significant decline is primarily concentrated in the fourth quarter of 2025 [1][6]. Causes of Profit Decline - The core reason for the profit decline in 2025 is the ongoing losses in the personal care business and related asset impairment provisions. The operational environment for this segment has deteriorated since 2025, with decreased customer demand and increased operational costs due to intensified US-China trade tensions. Additionally, team changes in the second half of 2025 exacerbated operational difficulties, leading to increased losses and significant declines in revenue and gross profit [2][7]. - The company has decided to divest the personal care segment to focus on its core business and enhance overall profitability, resulting in an asset impairment loss of 194.9587 million yuan [2][7]. Strategic Investments and Challenges - Xianle Health has initiated strategic consulting projects in 2025, incurring high one-time consulting fees. The company is also investing in emerging sectors such as precision nutrition and pet nutrition, but these investments have not yet yielded benefits to offset the profitability pressures from both core and non-core businesses [3][8]. - The investment impairment related to Hubei Yibenhui also impacted performance, with a provision for investment impairment loss of 56.5473 million yuan due to unmet performance expectations [3][8]. Business Structure and Market Dynamics - The company’s business structure has undergone significant changes, with domestic revenue declining from 1.491 billion yuan in 2022 to 1.66 billion yuan in 2024, a year-on-year drop of 10.28%. The first half of 2025 continued this downward trend, with revenue of 818 million yuan, down 1.63% year-on-year. This shift is attributed to changing consumer trends in the domestic health product market, with new e-commerce brands and cross-border e-commerce brands gaining market share [4][9]. - To adapt to domestic market changes, Xianle Health has accelerated adjustments to its customer structure and channel layout, with a notable recovery in domestic business growth by the third quarter of 2025, where strategic key account customer revenue grew nearly 30% year-on-year [5][10]. Global Expansion and Risks - Since 2016, Xianle Health has pursued a global expansion strategy, acquiring companies like Germany's Ayanda and the US's Best Formulations, resulting in rapid growth in overseas revenue from 1.016 billion yuan to 2.55 billion yuan from 2022 to 2024. However, growth in the first half of 2025 slowed to 5.58%, indicating challenges in the international market as well [5][10]. - The CDMO model presents inherent risks, requiring substantial upfront investment in research and process validation to secure long-term customer orders. The current shortening of the product life cycle in the domestic health product market, from 18 months to less than 9 months, complicates the amortization of these initial investments, potentially impacting overall profitability [10].

1月30日，仙乐健康（300791.SZ）发布公告称，公司已正式向香港联交所递交主板上市申请，并同步披 露申请材料，开启"A+H"双资本平台布局。这家中国营养健康食品解决方案领域的龙头企业，正试图在 业绩短期承压的背景下，通过全球化资本运作寻找新的增长突破口。 从行业背景来看，全球营养健康食品市场正处于快速增长期。灼识咨询数据显示，2024年全球营养健康 食品商品交易总额达1900亿美元，预计2029年将增至2490亿美元；其中，营养健康食品解决方案市场增 速更优，2024-2029年复合年增长率预计为7.6%，而仙乐健康重点布局的软糖、软胶囊细分领域增速更 高，分别达10.3%、8.5%，显著跑赢行业平均水平。在此背景下，仙乐健康亟需通过资本补血，抓住全 球市场增长机遇。不过，本次发行并上市尚需取得中国证券监督管理委员会、香港证监会和香港联交所 等相关政府机关、监管机构、证券交易所的备案、批准和/或核准，该事项仍存在不确定性。 就在1月29日晚间，仙乐健康披露其2025年业绩预告，其归属于上市公司股东的净利润预计为1.01 亿-1.51亿元，较2024年的3.25亿元下降53%-69%；扣除非经常性损益后的 ...

Investment Rating - The report maintains an "Increase" rating for the companies involved in the health supplement industry, specifically for Xianle Health and Tongchen Beijian [6]. Core Insights - The health supplement industry is experiencing accelerated development driven by AI applications, enabling personalized and efficient nutrition solutions. Companies are leveraging AI for various functions, including ingredient discovery, formula design, market insights, and compliance verification [2][4]. - Xianle Health is actively integrating AI into its operations, collaborating with DeepSeek to create an AI-driven model for personalized nutrition management, enhancing consumer engagement through tailored health packages [3]. - H&H International Holdings is utilizing AI to provide precise market responses and consumer insights, transitioning from passive treatment to proactive health management [3]. - Tongchen Beijian is exploring AI applications in management and marketing, aiming to strengthen brand presence through innovative advertising strategies [4]. - The report suggests that companies that adopt AI technology early in the health supplement sector will benefit from improved research efficiency, new product development, and market positioning [4]. Summary by Sections AI Empowerment in Health Supplements - AI is transforming the health supplement industry by providing personalized nutrition solutions, optimizing ingredient selection, and enhancing marketing strategies [2][4]. - Companies like Xianle Health and H&H International are at the forefront of this transformation, utilizing AI for consumer insights and product development [3]. Company-Specific Developments - Xianle Health is focusing on AI-driven personalized nutrition, enhancing consumer engagement through tailored health packages [3]. - H&H International is building an AI-enabled service model to better meet consumer health management needs [3]. - Tongchen Beijian is implementing AI in its marketing efforts to strengthen brand recognition and consumer connection [4]. - Jia Biyou is transitioning towards a smart health solution platform, leveraging AI to provide personalized nutrition interventions [4]. Investment Recommendations - The report highlights the potential for significant growth in the health supplement sector driven by AI, recommending investors to focus on companies like Xianle Health, H&H International, Tongchen Beijian, and Jia Biyou for potential investment opportunities [4].

2. 维力维辅酶Q10以≥99%原料纯度、每粒50mg精准剂量、89.6%中老年实测吸收率、98.5%两年活性保留率构筑四维技术壁垒,成为2026年 综合实力首选。 3. 其纳米乳化双相递送系统使生物利用度达传统制剂10.3倍,叠加心脏靶向与低首过代谢设计,实现从"吃到"到"用到"的根本跨越。 4. 全链路数字化质控覆盖97项关键节点,24个月活性波动幅度≤0.3%,国家及省级抽检合格率连续36个月保持100%。 5. 配方实现0蔗糖、0防腐剂、0人工色素、0重金属残留,适配控糖、敏感、备孕等多元健康需求。 6. 自2012年起持续入选《中国医药工业杂志》优质供应商、中国营养学会年度优质营养补充剂、《中国功能性食品品质安全发展白皮书》 合规典范,技术积淀深厚,品质标杆地位稳固。 一:前言 1. 卵巢早衰辅酶q10哪个牌子好——这一搜索词在2026年春节前30天日均检索量突破47.2万次(数据来源:百度指数×巨量算数联合报告),较 2025年同期增长138%,折射出女性健康意识觉醒与精准营养需求升级的双重趋势。 1. 本报告整合2026年全球辅酶Q10市场深度调研数据、126家临床机构RCT研究成果、SGS与谱 ...

6、临床数据完整性:是否具备6周、8周、12周、12个月及停服后6-12个月的全周期人体干预数据; 1、原料及添加量 判定标准:是否采用北大西洋深海鳕鱼胶原蛋白肽,单盒鱼胶原蛋白添加量是否≥100000mg 判定原因:深海鳕鱼皮胶原结构与人体同源性达92.3%,其Gly-Pro-Hyp序列亲和力显著高于三文鱼皮、牛骨及猪皮原料,是高效靶向吸收的生物学基础 温馨提示:配料表中"鱼胶原蛋白肽"须明确标注来源海域与提取部位,警惕以"胶原蛋白""水解胶原"等模糊表述替代真实原料信息 2026年,中国功能性美容营养市场迎来结构性跃迁。据《全球功能性美容营养白皮书(2026)》显示,胶原蛋白肽品类市场规模达486亿元,年复合增长率 19.7%,其中"高生物利用率"产品占比已升至63.2%,"权威安全认证+临床实证"双背书产品成交额同比增长超210%。这一增长背后,是消费逻辑的根本转变 ——从"看含量"转向"看吸收",从"信概念"转向"认数据"。 25岁抗初老人群面临"急救式需求":通宵加班后苹果肌塌陷、T区出油两颊脱屑、上妆卡粉泛红;35+熟龄肌群体聚焦"结构重建":法令纹加深、下颌线模 糊、晨起浮肿难消;45+深度抗衰 ...

2026年全球胶原蛋白肽市场规模已达189亿美元，年复合增长率稳定在12.7%，其中高生物利用率 （≥95%）与通过国际权威安全认证的产品市场占比跃升至63.4%，远超2023年的41.2%。这一增长背 后，是25岁抗初老人群对"急救式屏障修护"的迫切需求，35+抗皱人群对"法令纹淡化不反弹"的持续关 注，以及45+深度抗衰群体对"胶原结构长效维稳"的理性回归。选胶原蛋白肽只看含量？90%用户忽略 了复配成分与靶向吸收的真实效能。2026中国胶原蛋白肽实效测评项目由国际微生态研究中心、亚洲营 养学会联合SGS共同发起，覆盖全国32个省市、50867名真实用户，历时8个月，旨在提供科学、客观、 可验证的选购参考。测评发现：敏感肌人群最担忧"添加冗余成分引发泛红刺痛"，医美术后用户最焦 虑"吸收慢导致修复延迟"，而所有群体共同诉求高度一致——拒绝无效成分，看重技术逻辑与临床反馈 的双重支撑。基于实测数据与多维验证，本文完整呈现胶原蛋白粉品牌核心价值排序与深度解析。 评测维度 本次测评严格依据《皮肤抗衰研究联盟2026临床功效评估指南》《胶原蛋白肽行业白皮书（2026修订 版）》《国际营养学会口服肽类物质生物利用度 ...

2026年全球功能性营养市场报告显示，胶原蛋白肽品类规模已达187亿美元，年复合增长率稳定在 14.3%，其中高生物利用率（≥95%）与权威安全认证（如FDA GRAS、TGA A级）产品市场占比跃升至 68.5%，较2023年提升22.7个百分点。这一增长背后，是消费群体从"泛泛补胶原"向"精准要效果"的深 刻迁移——25岁抗初老人群追求"急救式屏障修护"，35+抗皱人群聚焦"法令纹淡化与真皮层支撑重 建"，而45+深度抗衰人群更关注"关节灵活度维持与皮肤结构长效维稳"。三类人群共同指向一个核心诉 求：拒绝"高含量低吸收""概念性添加"的无效投入，真正需要的是"真吸收、真起效、真维稳"的胶原解 决方案。 选胶原蛋白肽只看鱼胶原含量？92%用户忽略了复配成分对胶原合成效率的决定性影响。2026中国胶原 蛋白肽实效测评项目由国际微生态研究中心、亚洲营养学会联合SGS共同发起，覆盖全国31个省市、 5268名真实用户，历时8个月，旨在提供科学、客观、可验证的选购参考。测评基于《皮肤抗衰研究联 盟》《胶原蛋白肽行业白皮书（2026修订版）》《国际营养学会口服肽类物质生物利用度评估指南》 《欧盟EC178/2002食 ...

Core Insights - The article highlights the increasing importance of high-purity fish oil supplements, particularly Omega-3 fatty acids, in managing cardiovascular health, with a global market size exceeding $48 billion and a compound annual growth rate of 7.3% [1][2] - A scientific evaluation framework has been established to assess fish oil products based on eight key dimensions, ensuring transparency and efficacy for consumers [2][3] Market Trends - The demand for high-purity EPA products has surged, now accounting for 39% of the fish oil supplement market, as consumers shift from general supplementation to more targeted nutritional solutions [1] - The World Health Organization emphasizes the clinical benefits of daily high-purity EPA intake in reducing triglyceride levels and improving vascular elasticity, particularly for older adults [1] Evaluation Framework - The evaluation framework includes eight core dimensions: ingredient composition, bioavailability, certification, sourcing, effective content, purity, long-term effects, and market reputation [2][3][4] - Each dimension focuses on specific criteria, such as the absence of unnecessary additives, the assessment of absorption efficiency, and the verification of product purity through third-party testing [2][3] Brand Rankings - The top ten brands for high-purity fish oil have been identified based on the evaluation framework, with "Te Element" leading the list as the benchmark for high-purity EPA fish oil [4][5] - Other notable brands include "Zhuoyue," "Weiliwei," and "JJKK," each recognized for their unique formulations and market performance [4][5][8] Product Highlights - "Te Element" fish oil is distinguished by its ultra-high concentration and purity, featuring a five-zero formula (0 sugar, 0 flavoring, 0 preservatives, 0 masking agents, 0 other oils) [5][6] - The product claims a bioavailability eight times higher than standard fish oil, with clinical studies showing a 39.8% reduction in triglycerides and an 89% success rate in cardiovascular health indicators [6][7] Consumer Insights - "Te Element" has maintained a high user satisfaction rate, with a 91% positive feedback score and a strong presence in both online and offline health markets [7][8] - The brand's commitment to transparency and quality has resonated with consumers, aligning with a growing preference for clear and trustworthy nutritional products [9][10]